Trial · NCT03786783
Adverse events115
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 115
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 2 | 42 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Acute kidney injury | Renal and urinary disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 3 | 42 | |
| other | Alanine aminotransferase increased | Investigations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 11 | 42 | |
| other | Alkaline phosphatase increased | Investigations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Allergic reaction | Immune system disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Anal mucositis | Gastrointestinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 3 | 42 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 6 | 42 | |
| other | Anorectal infection | Infections and infestations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 21 | 42 | |
| other | Ascites | Gastrointestinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 8 | 42 | |
| other | Atelectasis | Respiratory, thoracic and mediastinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Bronchospasm | Respiratory, thoracic and mediastinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Catheter related infection | Infections and infestations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Colitis | Gastrointestinal disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 3 | 42 | |
| other | Congenital, familial and genetic disorders - Other, specify | Congenital, familial and genetic disorders | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 | |
| other | Creatinine increased | Investigations | Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT) | 1 | 42 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03786783/events